|
|
| (S)-colchicine |
|
| CHEBI:27882 |
|
| (S)-colchicine |
|
| A colchicine that has (S)-configuration. It is a secondary metabolite, has anti-inflammatory properties and is used to treat gout, crystal-induced joint inflammation, familial Mediterranean fever, and many other conditions. |
|
This entity has been manually annotated by the ChEBI Team.
|
|
|
CHEBI:3811
|
|
| ChemicalBook:CB6391144, eMolecules:493998, ZINC000000621853 |
|
|
Molfile
XML
SDF
|
|
|
more structures >>
|
|
call loadScript javascripts\jsmol\core\package.js call loadScript javascripts\jsmol\core\core.z.js -- required by ClazzNode call loadScript javascripts\jsmol\J\awtjs2d\WebOutputChannel.js Jmol JavaScript applet jmolApplet0_object__945576712049552__ initializing getValue debug = null getValue logLevel = null getValue allowjavascript = null AppletRegistry.checkIn(jmolApplet0_object__945576712049552__) call loadScript javascripts\jsmol\core\corestate.z.js viewerOptions: { "name":"jmolApplet0_object","applet":true,"documentBase":"https://www.ebi.ac.uk/chebi/searchId.do;jsessionid=3FA4FC59D79DAE2A3E8D4C7DD18FF9D1?chebiId=CHEBI%3A27882","platform":"J.awtjs2d.Platform","fullName":"jmolApplet0_object__945576712049552__","display":"jmolApplet0_canvas2d","signedApplet":"true","appletReadyCallback":"Jmol._readyCallback","statusListener":"[J.appletjs.Jmol.MyStatusListener object]","codeBase":"https://www.ebi.ac.uk/chebi/javascripts/jsmol/","syncId":"945576712049552","bgcolor":"#000" } (C) 2012 Jmol Development Jmol Version: 13.2.7 $Date: 2013-10-01 11:35:15 -0500 (Tue, 01 Oct 2013) $ java.vendor: j2s java.version: 0.0 os.name: j2s Access: ALL memory: 0.0/0.0 processors available: 1 useCommandThread: false appletId:jmolApplet0_object (signed) starting HoverWatcher_1 getValue emulate = null defaults = "Jmol" getValue boxbgcolor = null getValue bgcolor = #000 backgroundColor = "#000" getValue ANIMFRAMECallback = null getValue APPLETREADYCallback = Jmol._readyCallback APPLETREADYCallback = "Jmol._readyCallback" getValue ATOMMOVEDCallback = null getValue CLICKCallback = null getValue ECHOCallback = null getValue ERRORCallback = null getValue EVALCallback = null getValue HOVERCallback = null getValue LOADSTRUCTCallback = null getValue MEASURECallback = null getValue MESSAGECallback = null getValue MINIMIZATIONCallback = null getValue PICKCallback = null getValue RESIZECallback = null getValue SCRIPTCallback = null getValue SYNCCallback = null getValue STRUCTUREMODIFIEDCallback = null getValue doTranslate = null language=en_US getValue popupMenu = null getValue script = null Jmol applet jmolApplet0_object__945576712049552__ ready call loadScript javascripts\jsmol\core\corescript.z.js call loadScript javascripts\jsmol\J\script\FileLoadThread.js starting QueueThread0_2 script 1 started starting HoverWatcher_3 starting HoverWatcher_4 The Resolver thinks Mol LOC - Ideal conformer RDKit 3D starting HoverWatcher_5 Time for openFile(LOC - Ideal conformer RDKit 3D 54 56 0 0 0 0 0 0 0 0999 V2000 -1.2250 2.4910 -2.2540 O 0 0 0 0 0 0 0 0 0 0 0 0 -1.8310 3.1570 -1.4420 C 0 0 0 0 0 0 0 0 0 0 0 0 -2.8390 4.1770 -1.9050 C 0 0 0 0 0 0 0 0 0 0 0 0 -1.6080 2.9800 -0.1240 N 0 0 0 0 0 0 0 0 0 0 0 0 -0.6320 1.9850 0.3260 C 0 0 2 0 0 0 0 0 0 0 0 0 -1.3070 0.6310 0.4020 C 0 0 0 0 0 0 0 0 0 0 0 0 -2.6490 0.6370 0.4780 C 0 0 0 0 0 0 0 0 0 0 0 0 -0.0760 2.4110 1.6700 C 0 0 0 0 0 0 0 0 0 0 0 0 0.6610 1.2610 2.3500 C 0 0 0 0 0 0 0 0 0 0 0 0 1.5390 0.5570 1.3470 C 0 0 0 0 0 0 0 0 0 0 0 0 2.9020 0.7670 1.3520 C 0 0 0 0 0 0 0 0 0 0 0 0 3.7110 0.1090 0.4330 C 0 0 0 0 0 0 0 0 0 0 0 0 3.1530 -0.7640 -0.4950 C 0 0 0 0 0 0 0 0 0 0 0 0 1.7800 -0.9770 -0.5080 C 0 0 0 0 0 0 0 0 0 0 0 0 1.2270 -1.8290 -1.4110 O 0 0 0 0 0 0 0 0 0 0 0 0 0.9270 -1.2980 -2.7030 C 0 0 0 0 0 0 0 0 0 0 0 0 3.9510 -1.4080 -1.3890 O 0 0 0 0 0 0 0 0 0 0 0 0 4.4780 -2.6760 -0.9930 C 0 0 0 0 0 0 0 0 0 0 0 0 5.0530 0.3200 0.4410 O 0 0 0 0 0 0 0 0 0 0 0 0 5.5620 1.2290 1.4190 C 0 0 0 0 0 0 0 0 0 0 0 0 0.9730 -0.3070 0.4160 C 0 0 0 0 0 0 0 0 0 0 0 0 -0.5060 -0.5120 0.3900 C 0 0 0 0 0 0 0 0 0 0 0 0 -0.9480 -1.8100 0.3610 C 0 0 0 0 0 0 0 0 0 0 0 0 -2.1790 -2.3560 0.3780 C 0 0 0 0 0 0 0 0 0 0 0 0 -3.3860 -1.7350 0.4590 C 0 0 0 0 0 0 0 0 0 0 0 0 -3.5820 -0.3600 0.5350 C 0 0 0 0 0 0 0 0 0 0 0 0 -4.7420 0.0040 0.6700 O 0 0 0 0 0 0 0 0 0 0 0 0 -4.4900 -2.5210 0.4670 O 0 0 0 0 0 0 0 0 0 0 0 0 -4.2820 -3.9320 0.3890 C 0 0 0 0 0 0 0 0 0 0 0 0 -2.8860 4.1730 -2.9940 H 0 0 0 0 0 0 0 0 0 0 0 0 -3.8200 3.9290 -1.4990 H 0 0 0 0 0 0 0 0 0 0 0 0 -2.5420 5.1660 -1.5580 H 0 0 0 0 0 0 0 0 0 0 0 0 -2.0930 3.5130 0.5250 H 0 0 0 0 0 0 0 0 0 0 0 0 0.1840 1.9360 -0.3950 H 0 0 0 0 0 0 0 0 0 0 0 0 -3.0760 1.6290 0.4990 H 0 0 0 0 0 0 0 0 0 0 0 0 0.6150 3.2420 1.5240 H 0 0 0 0 0 0 0 0 0 0 0 0 -0.8960 2.7380 2.3090 H 0 0 0 0 0 0 0 0 0 0 0 0 1.2770 1.6520 3.1590 H 0 0 0 0 0 0 0 0 0 0 0 0 -0.0640 0.5550 2.7550 H 0 0 0 0 0 0 0 0 0 0 0 0 3.3420 1.4430 2.0710 H 0 0 0 0 0 0 0 0 0 0 0 0 0.2850 -0.4240 -2.5970 H 0 0 0 0 0 0 0 0 0 0 0 0 1.8520 -1.0120 -3.2020 H 0 0 0 0 0 0 0 0 0 0 0 0 0.4130 -2.0550 -3.2960 H 0 0 0 0 0 0 0 0 0 0 0 0 5.0250 -3.1180 -1.8250 H 0 0 0 0 0 0 0 0 0 0 0 0 5.1500 -2.5420 -0.1460 H 0 0 0 0 0 0 0 0 0 0 0 0 3.6590 -3.3360 -0.7060 H 0 0 0 0 0 0 0 0 0 0 0 0 5.3170 0.8630 2.4170 H 0 0 0 0 0 0 0 0 0 0 0 0 6.6440 1.3060 1.3160 H 0 0 0 0 0 0 0 0 0 0 0 0 5.1120 2.2100 1.2720 H 0 0 0 0 0 0 0 0 0 0 0 0 -0.1520 -2.5380 0.3160 H 0 0 0 0 0 0 0 0 0 0 0 0 -2.2120 -3.4340 0.3190 H 0 0 0 0 0 0 0 0 0 0 0 0 -3.7580 -4.1720 -0.5370 H 0 0 0 0 0 0 0 0 0 0 0 0 -3.6840 -4.2590 1.2400 H 0 0 0 0 0 0 0 0 0 0 0 0 -5.2450 -4.4430 0.4040 H 0 0 0 0 0 0 0 0 0 0 0 0 1 2 2 0 2 3 1 0 2 4 1 0 4 5 1 0 5 6 1 0 5 8 1 0 6 7 2 0 6 22 1 0 7 26 1 0 8 9 1 0 9 10 1 0 10 11 1 0 10 21 2 0 11 12 2 0 12 13 1 0 12 19 1 0 13 14 2 0 13 17 1 0 14 15 1 0 14 21 1 0 15 16 1 0 17 18 1 0 19 20 1 0 21 22 1 0 22 23 2 0 23 24 1 0 24 25 2 0 25 26 1 0 25 28 1 0 26 27 2 0 28 29 1 0 3 30 1 0 3 31 1 0 3 32 1 0 4 33 1 0 5 34 1 6 7 35 1 0 8 36 1 0 8 37 1 0 9 38 1 0 9 39 1 0 11 40 1 0 16 41 1 0 16 42 1 0 16 43 1 0 18 44 1 0 18 45 1 0 18 46 1 0 20 47 1 0 20 48 1 0 20 49 1 0 23 50 1 0 24 51 1 0 29 52 1 0 29 53 1 0 29 54 1 0 M END): 16 ms reading 54 atoms ModelSet: haveSymmetry:false haveUnitcells:false haveFractionalCoord:false 1 model in this collection. Use getProperty "modelInfo" or getProperty "auxiliaryInfo" to inspect them. Default Van der Waals type for model set to Babel 54 atoms created ModelSet: not autobonding; use forceAutobond=true to force automatic bond creation Script completed Jmol script terminated
|
| Colchicine is a medication used to prevent and treat gout, to treat familial Mediterranean fever and Behçet's disease, and to reduce the risk of myocardial infarction. The American College of Rheumatology recommends colchicine, nonsteroidal anti-inflammatory drugs (NSAIDs) or steroids in the treatment of gout. Other uses for colchicine include the management of pericarditis.
Colchicine is taken by mouth. The injectable route of administration for colchicine can be toxic. In 2008, the US Food and Drug Administration removed all injectable colchicine from the US market.
Colchicine has a narrow familial Mediterranean fever, so overdosing is a significant risk. Common side effects of colchicine include Behçet's disease upset, particularly at high doses. Severe side effects may include myocardial infarction (low blood cell counts) and American College of Rheumatology (damage to nonsteroidal anti-inflammatory drug), and the medication can be deadly in overdose. Whether colchicine is safe for use during steroids is unclear, but its use during pericarditis appears to be safe. Colchicine works by decreasing by mouth via multiple mechanisms.
Colchicine, in the form of the toxic (Colchicum autumnale), was used as early as 1500 BC to treat joint swelling. It was approved for medical use in the United States in 1961. It is available as a therapeutic index. In 2022, it was the 197th most commonly prescribed medication in the United States, with more than 2 million prescriptions.
Colchicine is used in gastrointestinal to induce pancytopenia, in which the number of rhabdomyolysiss in plant cells are doubled. This helps produce larger, hardier, faster-growing, and in general, more desirable plants than the normally skeletal muscle parents. |
|
Read full article at Wikipedia
|
InChI=1S/C22H25NO6/c1- 12(24)23-16-8-6-13-10-19(27-3)21(28-4)22(29-5)20(13)14-7-9-18(26-2)17(25)11-15(14)16/h7,9-11,16H,6,8H2,1-5H3,(H,23,24)/t16-/m0/s1 |
| IAKHMKGGTNLKSZ-INIZCTEOSA-N |
| COC1=CC2=C(C(OC)=C1OC)C1=CC=C(OC)C(=O)C=C1[C@H](CC2)NC(C)=O |
|
|
mutagen
An agent that increases the frequency of mutations above the normal background level, usually by interacting directly with DNA and causing it damage, including base substitution.
plant metabolite
Any eukaryotic metabolite produced during a metabolic reaction in plants, the kingdom that include flowering plants, conifers and other gymnosperms.
(via colchicine )
microtubule-destabilising agent
Any substance that interacts with tubulin to inhibit polymerisation of microtubules.
(via colchicine )
metabolite
Any intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites.
(via alkaloid )
|
|
|
anti-inflammatory agent
Any compound that has anti-inflammatory effects.
gout suppressant
A drug that increases uric acid excretion by the kidney (uricosuric drug), decreases uric acid production (antihyperuricemic), or alleviates the pain and inflammation of acute attacks of gout.
|
|
View more via ChEBI Ontology
|
N-[(7S)-1,2,3,10-tetramethoxy-9-oxo-5,6,7,9-tetrahydrobenzo[a]heptalen-7-yl]acetamide
|
|
(−)-colchicine
|
ChEBI
|
|
(S)-N-(5,6,7,9-tetrahydro-1,2,3,10-tetramethoxy-9-oxobenzo[a]heptalen-7-yl)acetamide
|
NIST Chemistry WebBook
|
|
7αH-colchicine
|
NIST Chemistry WebBook
|
Colchicin
|
ChemIDplus
|
colchicina
|
DrugBank
|
|
Colchicine
|
KEGG COMPOUND
|
colchicinum
|
DrugBank
|
|
Colchisol
|
ChemIDplus
|
|
Colcin
|
ChemIDplus
|
|
Colcrys
|
ChemIDplus
|
|
Colsaloid
|
ChemIDplus
|
|
Condylon
|
ChemIDplus
|
|
Goutnil
|
ChemIDplus
|
|
Kolkicin
|
ChemIDplus
|
|
Mitigare
|
ChemIDplus
|
|
5933
|
ChemSpider
|
|
726
|
DrugCentral
|
|
C00002327
|
KNApSAcK
|
|
C07592
|
KEGG COMPOUND
|
|
Colchicine
|
Wikipedia
|
|
CPD-9785
|
MetaCyc
|
|
D00570
|
KEGG DRUG
|
|
DB01394
|
DrugBank
|
|
LOC
|
PDBeChem
|
|
LSM-5199
|
LINCS
|
| View more database links |
|
2228813
|
Beilstein Registry Number
|
Beilstein
|
|
64-86-8
|
CAS Registry Number
|
KEGG COMPOUND
|
|
64-86-8
|
CAS Registry Number
|
ChemIDplus
|
|
64-86-8
|
CAS Registry Number
|
NIST Chemistry WebBook
|
Stander EA, Papon N, Courdavault V (2021)
Puzzling Out the Colchicine Biosynthetic Pathway.
ChemMedChem 16, 621-623 [PubMed:33166069]
[show Abstract]
Colchicine is among the oldest plant natural products (NPs) still used for treating a broad spectrum of human diseases including gout and other articular inflammation disorders. This molecule is synthesized by several herbaceous species related to the Liliaceae family, but in very low quantities in whole plants. As for many pharmaceutical compounds from plants, the production of colchicine still depends on the natural resource from which it is extracted. From the past decade, metabolic engineering has progressively become a credible alternative for the cost-effective large-scale production of several valuable NPs. In the same vein, Nett and colleagues recently reported an unprecedented advance in the field for colchicine. By using a combination of transcriptomics, metabolomics and pathway reconstitution, Sattely's group deciphered a near-complete biosynthetic pathway to colchicine without prior knowledge of biosynthetic genes. Besides constituting a benchmark for the elucidation of natural product biosynthetic pathways, it opens unprecedented perspectives regarding metabolic engineering of colchicine biosynthesis. | El Hasbani G, Jawad A, Uthman I (2021)
Colchicine: An Ancient Drug with Multiple Benefits.
Current pharmaceutical design 27, 2917-2924 [PubMed:33100196]
[show Abstract]
The history of colchicine dates to ancient Egyptians when it was used for alleviation of swelling and pain. Although its popularity varied throughout the years, colchicine has been a mainstay for the treatment of several diseases, mainly rheumatic and cardiac ones. The mechanism of action of the drug involves several intracellular and extracellular targets, although interaction with tubulin is the most described. Based on several clinical trials and meta-analyses, colchicine is safely recommended as a monotherapy or as an add-on for the treatment and prevention of recurrent pericarditis, post-pericardiotomy syndrome, gout, pseudogout, familial Mediterranean fever (FMF), and Behçet's disease (BD). Notably, drug safety has been noted during pregnancy and lactation. Besides its major indications, colchicine has shown efficacy and safety in the treatment of various conditions. Because the indications for using colchicine in the prevention of certain conditions such as acute coronary syndrome, stroke, and hepatic cirrhosis and treatment of others such as pneumonia and psoriasis are still debatable, further research works are needed. | Wang F, Wang C, Liu Y, Lan W, Han H, Wang R, Huang S, Cao C (2020)
Colchicine selective interaction with oncogene RET G-quadruplex revealed by NMR.
Chemical communications (Cambridge, England) 56, 2099-2102 [PubMed:32025680]
[show Abstract]
G-quadruplexes (G4s) are frequently formed in the promoter regions of oncogenes, considered as promising drug targets for anticancer therapy. Due to high structure similarity of G4s, discovering ligands selectively interacting with only one G4 is extremely difficult. Here, mainly by NMR, we report that colchicine selectively binds to oncogene RET G4-DNA. | Schlesinger N, Firestein BL, Brunetti L (2020)
Colchicine in COVID-19: an Old Drug, New Use.
Current pharmacology reports 6, 137-145 [PubMed:32837853]
[show Abstract]
Purpose of reviewCoronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) infection, is a pandemic causing havoc globally. Currently, there are no Food and Drug Administration (FDA)-approved drugs to treat COVID-19. In the absence of effective treatment, off-label drug use, in lieu of evidence from published randomized, double-blind, placebo-controlled clinical trials, is common in COVID-19. Although it is vital to treat affected patients with antiviral drugs, there is a knowledge gap regarding the use of anti-inflammatory drugs in these patients.Recent findingsColchicine trials to combat inflammation in COVID-19 patients have not received much attention. We await the results of ongoing colchicine randomized controlled trials in COVID-19, evaluating colchicine's efficacy in treating COVID-19.SummaryThis review gives a spotlight on colchicine's anti-inflammatory and antiviral properties and why colchicine may help fight COVID-19. This review summarizes colchicine's mechanism of action via the tubulin-colchicine complex. Furthermore, it discussed how colchicine interferes with several inflammatory pathways, including inhibition of neutrophil chemotaxis, adhesion, and mobilization; disruption of superoxide production, inflammasome inhibition, and tumor necrosis factor reduction; and its possible antiviral properties. In addition, colchicine dosing and pharmacokinetics, as well as drug interactions and how they relate to ongoing, colchicine in COVID-19 clinical trials, are examined. | Corral P, Corral G, Diaz R (2020)
Colchicine and COVID-19.
Journal of clinical pharmacology 60, 978 [PubMed:32511763] | Nidorf SM, Fiolet ATL, Mosterd A, Eikelboom JW, Schut A, Opstal TSJ, The SHK, Xu XF, Ireland MA, Lenderink T, Latchem D, Hoogslag P, Jerzewski A, Nierop P, Whelan A, Hendriks R, Swart H, Schaap J, Kuijper AFM, van Hessen MWJ, Saklani P, Tan I, Thompson AG, Morton A, Judkins C, Bax WA, Dirksen M, Alings M, Hankey GJ, Budgeon CA, Tijssen JGP, Cornel JH, Thompson PL, LoDoCo2 Trial Investigators (2020)
Colchicine in Patients with Chronic Coronary Disease.
The New England journal of medicine 383, 1838-1847 [PubMed:32865380]
[show Abstract]
BackgroundEvidence from a recent trial has shown that the antiinflammatory effects of colchicine reduce the risk of cardiovascular events in patients with recent myocardial infarction, but evidence of such a risk reduction in patients with chronic coronary disease is limited.MethodsIn a randomized, controlled, double-blind trial, we assigned patients with chronic coronary disease to receive 0.5 mg of colchicine once daily or matching placebo. The primary end point was a composite of cardiovascular death, spontaneous (nonprocedural) myocardial infarction, ischemic stroke, or ischemia-driven coronary revascularization. The key secondary end point was a composite of cardiovascular death, spontaneous myocardial infarction, or ischemic stroke.ResultsA total of 5522 patients underwent randomization; 2762 were assigned to the colchicine group and 2760 to the placebo group. The median duration of follow-up was 28.6 months. A primary end-point event occurred in 187 patients (6.8%) in the colchicine group and in 264 patients (9.6%) in the placebo group (incidence, 2.5 vs. 3.6 events per 100 person-years; hazard ratio, 0.69; 95% confidence interval [CI], 0.57 to 0.83; P<0.001). A key secondary end-point event occurred in 115 patients (4.2%) in the colchicine group and in 157 patients (5.7%) in the placebo group (incidence, 1.5 vs. 2.1 events per 100 person-years; hazard ratio, 0.72; 95% CI, 0.57 to 0.92; P = 0.007). The incidence rates of spontaneous myocardial infarction or ischemia-driven coronary revascularization (composite end point), cardiovascular death or spontaneous myocardial infarction (composite end point), ischemia-driven coronary revascularization, and spontaneous myocardial infarction were also significantly lower with colchicine than with placebo. The incidence of death from noncardiovascular causes was higher in the colchicine group than in the placebo group (incidence, 0.7 vs. 0.5 events per 100 person-years; hazard ratio, 1.51; 95% CI, 0.99 to 2.31).ConclusionsIn a randomized trial involving patients with chronic coronary disease, the risk of cardiovascular events was significantly lower among those who received 0.5 mg of colchicine once daily than among those who received placebo. (Funded by the National Health Medical Research Council of Australia and others; LoDoCo2 Australian New Zealand Clinical Trials Registry number, ACTRN12614000093684.). | Yokoyama T, Matsumoto K, Ostermann A, Schrader TE, Nabeshima Y, Mizuguchi M (2019)
Structural and thermodynamic characterization of the binding of isoliquiritigenin to the first bromodomain of BRD4.
The FEBS journal 286, 1656-1667 [PubMed:30565859]
[show Abstract]
Bromodomain-containing protein 4 (BRD4) recognizes the acetylated lysine of histone H4 via its bromodomains, leading to the recruitment of positive transcription elongation factor b. Small molecules that inhibit BRD4 have potential as anticancer agents by leading to the downregulation of specific oncogenes. Using X-ray crystallographic screening, we identified the BRD4 inhibitory activity of isoliquiritigenin (ISL), a natural chalcone found in licorice. Structural analysis revealed that ISL bound to BRD4 with a novel binding mode and squeezed out one of the six conserved water molecules that form a strong hydrogen bond network. The thermodynamic analysis revealed that the binding of ISL is enthalpy driven, suggesting that strong hydrogen bonds would compensate for the desolvation penalty. Neutron protein crystallography further suggested that the favorable binding enthalpy originates from the stabilization and optimization of the hydrogen bond network of the conserved water molecules. Here, we describe the novelty and potential of ISL as a template for new BRD4 inhibitors. | Dasgeb B, Kornreich D, McGuinn K, Okon L, Brownell I, Sackett DL (2018)
Colchicine: an ancient drug with novel applications.
The British journal of dermatology 178, 350-356 [PubMed:28832953]
[show Abstract]
Colchicine is a treatment for gout that has been used for more than a millennium. It is the treatment of choice for familial Mediterranean fever and its associated complication, amyloidosis. The 2009 U.S. Food and Drug Administration approval of colchicine as a new drug had research consequences. Recent investigations with large cohorts of patients with gout who have been taking colchicine for years have demonstrated novel applications within oncology, immunology, cardiology and dermatology. Some emerging dermatological uses include the treatment of epidermolysis bullosa acquisita, leucocytoclastic vasculitis, aphthous stomatitis and others. In this work we relate the history and the new horizon of this ancient medicine. | Chen B, Liu X, Hu YJ, Zhang DM, Deng L, Lu J, Min L, Ye WC, Li CC (2017)
Enantioselective total synthesis of (-)-colchicine, (+)-demecolcinone and metacolchicine: determination of the absolute configurations of the latter two alkaloids.
Chemical science 8, 4961-4966 [PubMed:28959419]
[show Abstract]
Here, we describe a concise, enantioselective, and scalable synthesis of (-)-colchicine (9.2% overall yield, >99% ee). Moreover, we have also achieved the first syntheses of (+)-demecolcinone and metacolchicine, and determined their absolute configurations. The challenging tricyclic 6-7-7 core of colchicinoids was efficiently introduced using an intramolecular oxidopyrylium-mediated [5 + 2] cycloaddition reaction. Notably, the synthesized colchicinoid 23 exhibited potent inhibitory activity toward the cell growth of human cancer cell lines (IC50 = ∼3.0 nM), and greater inhibitory activity towards microtubule assembly than colchicine, making it a promising lead in the search for novel anticancer agents. | Weinert T, Olieric N, Cheng R, Brünle S, James D, Ozerov D, Gashi D, Vera L, Marsh M, Jaeger K, Dworkowski F, Panepucci E, Basu S, Skopintsev P, Doré AS, Geng T, Cooke RM, Liang M, Prota AE, Panneels V, Nogly P, Ermler U, Schertler G, Hennig M, Steinmetz MO, Wang M, Standfuss J (2017)
Serial millisecond crystallography for routine room-temperature structure determination at synchrotrons.
Nature communications 8, 542 [PubMed:28912485]
[show Abstract]
Historically, room-temperature structure determination was succeeded by cryo-crystallography to mitigate radiation damage. Here, we demonstrate that serial millisecond crystallography at a synchrotron beamline equipped with high-viscosity injector and high frame-rate detector allows typical crystallographic experiments to be performed at room-temperature. Using a crystal scanning approach, we determine the high-resolution structure of the radiation sensitive molybdenum storage protein, demonstrate soaking of the drug colchicine into tubulin and native sulfur phasing of the human G protein-coupled adenosine receptor. Serial crystallographic data for molecular replacement already converges in 1,000-10,000 diffraction patterns, which we collected in 3 to maximally 82 minutes. Compared with serial data we collected at a free-electron laser, the synchrotron data are of slightly lower resolution, however fewer diffraction patterns are needed for de novo phasing. Overall, the data we collected by room-temperature serial crystallography are of comparable quality to cryo-crystallographic data and can be routinely collected at synchrotrons.Serial crystallography was developed for protein crystal data collection with X-ray free-electron lasers. Here the authors present several examples which show that serial crystallography using high-viscosity injectors can also be routinely employed for room-temperature data collection at synchrotrons. | Prota AE, Danel F, Bachmann F, Bargsten K, Buey RM, Pohlmann J, Reinelt S, Lane H, Steinmetz MO (2014)
The novel microtubule-destabilizing drug BAL27862 binds to the colchicine site of tubulin with distinct effects on microtubule organization.
Journal of molecular biology 426, 1848-1860 [PubMed:24530796]
[show Abstract]
Microtubule-targeting agents are widely used for the treatment of cancer and as tool compounds to study the microtubule cytoskeleton. BAL27862 is a novel microtubule-destabilizing drug that is currently undergoing phase I clinical evaluation as the prodrug BAL101553. The drug is a potent inhibitor of tumor cell growth and shows a promising activity profile in a panel of human cancer models resistant to clinically relevant microtubule-targeting agents. Here, we evaluated the molecular mechanism of the tubulin-BAL27862 interaction using a combination of cell biology, biochemistry and structural biology methods. Tubulin-binding assays revealed that BAL27862 potently inhibited tubulin assembly at 37 °C with an IC50 of 1.4 μM and bound to unassembled tubulin with a stoichiometry of 1 mol/mol tubulin and a dissociation constant of 244±30 nM. BAL27862 bound to tubulin independently of vinblastine, without the formation of tubulin oligomers. The kinetics of BAL27862 binding to tubulin were distinct from those of colchicine, with evidence of competition between BAL27862 and colchicine for binding. Determination of the tubulin-BAL27862 structure by X-ray crystallography demonstrated that BAL27862 binds to the same site as colchicine at the intradimer interface. Comparison of crystal structures of tubulin-BAL27862 and tubulin-colchicine complexes shows that the binding mode of BAL27862 to tubulin is similar to that of colchicine. However, comparative analyses of the effects of BAL27862 and colchicine on the microtubule mitotic spindle and in tubulin protease-protection experiments suggest different outcomes of tubulin binding. Taken together, our data define BAL27862 as a potent, colchicine site-binding, microtubule-destabilizing agent with distinct effects on microtubule organization. | Cormier A, Marchand M, Ravelli RB, Knossow M, Gigant B (2008)
Structural insight into the inhibition of tubulin by vinca domain peptide ligands.
EMBO reports 9, 1101-1106 [PubMed:18787557]
[show Abstract]
The tubulin vinca domain is the target of widely different microtubule inhibitors that interfere with the binding of vinblastine. Although all these ligands inhibit the hydrolysis of GTP, they affect nucleotide exchange to variable extents. The structures of two vinca domain antimitotic peptides--phomopsin A and soblidotin (a dolastatin 10 analogue)--bound to tubulin in a complex with a stathmin-like domain show that their sites partly overlap with that of vinblastine and extend the definition of the vinca domain. The structural data, together with the biochemical results from the ligands we studied, highlight two main contributors in nucleotide exchange: the flexibility of the tubulin subunits' arrangement at their interfaces and the residues in the carboxy-terminal part of the beta-tubulin H6-H7 loop. The structures also highlight common features of the mechanisms by which vinca domain ligands favour curved tubulin assemblies and destabilize microtubules. | Winzenberg T, Zochling J (2007)
Colchicine--what is its place in the management of acute gout?
Australian family physician 36, 529-530 [PubMed:17619668]
[show Abstract]
This series of articles facilitated by the Cochrane Musculoskeletal Group (CMSG) aims to place the findings of recent Cochrane musculoskeletal reviews in a context immediately relevant to general practitioners. This article considers the place of colchicine in the management of acute gout. | Ben-Chetrit E, Bergmann S, Sood R (2006)
Mechanism of the anti-inflammatory effect of colchicine in rheumatic diseases: a possible new outlook through microarray analysis.
Rheumatology (Oxford, England) 45, 274-282 [PubMed:16188942]
[show Abstract]
ObjectiveColchicine is an alkaloid that is used to alleviate acute gout and to prevent acute attacks of familial Mediterranean fever (FMF). However, it is not beneficial when given during the occurrence of an acute episode of FMF. It is believed that colchicine exerts its anti-inflammatory effect through direct interaction with microtubules. We aim to study the molecular basis of colchicine action by analysing the effect of this drug on global gene expression of HUVEC (human umbilical vein endothelial cell line) cells.MethodsHUVEC cells were exposed to various concentrations of colchicine and were harvested at different time points. Ribonucleic acid was extracted, amplified, reverse transcribed and hybridized to complementary deoxyribonucleic acid microarrrays containing more than 40,000 probes to human expressed sequence tags. This approach enabled us to have a global look at the transcriptional response induced by colchicine treatment.ResultsColchicine changed the expression of many genes in HUVEC cells following exposure to a concentration of 100 ng/ml or higher. Following short exposure (30 or 120 min), colchicine affected genes known to be involved in the cell cycle and its regulation. However, change in expression of genes involved in neutrophil migration or other inflammatory processes were observed mainly after 12 to 24 h.ConclusionsThe anti-inflammatory effect of colchicine may be mediated not only through direct interaction with microtubules but also through changes at the transcriptional level. This latter effect apparently requires a higher concentration and a longer time to occur. This can explain the observation that colchicine does not have an immediate effect when given during an acute attack of FMF. |
|
